IDEXX (IDXX) Launches Canine Cancer Detection Panel in UK

IDEXX (IDXX) Launches Canine Cancer Detection Panel in UK Maham Fatima Sat, April 11, 2026 at 1:35 PM EDT 2 min read IDXX IDEXX Laboratories Inc. (NASDAQ: IDXX ) is one of the 9 Best QQQ Stocks to Buy Now . On April 01, IDEXX Laboratories announced the launch of the IDEXX Cancer Dx Panel in the UK, specifically for the early detection of lymphoma in at-risk dogs. This blood-based test is designed to integrate into both sick-pet diagnostics and routine wellness screenings, with results available to UK practices within 3 to 5 business days. The test aims to address a clinical need, as lymphoma accounts for ~25% of new canine cancer diagnoses, and early detection can occur up to 8 months before physical symptoms manifest. The panel offers 79% sensitivity and 99% specificity, providing clinicians with reliable insights that can include B-cell and T-cell phenotype classification for positive results. Beyond initial detection, early data indicate the test can be used to monitor patients during chemotherapy treatments. Each result includes comprehensive support from IDEXX Medical Consultants, including board-certified oncologists, as well as educational resources to help veterinarians communicate findings and next steps to pet owners. IDEXX Laboratories Inc. (NASDAQ:IDXX) highlighted strong market demand for the product, noting that 71% of UK pet owners have expressed interest in cancer screening for their pets. Since its 2025 launch in North America, ~6,000 practices have already a…